Showing 1881-1890 of 2657 results for "".
- Opus Genetics Presents Phentolamine Ophthalmic Solution 0.75% Improves Visual Acuity in Patients with Dim Light Disturbances, World Cornea Congress IXhttps://modernod.com/news/opus-genetics-presents-phentolamine-ophthalmic-solution-075-improves-visual-acuity-in-patients-with-dim-light-disturbances-world-cornea-congress-ix/2482711/Opus Genetics, Inc. shared the positive findings of their Phentolamine Ophthalmic Solution 0.75% to improve visual acuity in patients with dim light disturbances last week at the World Cornea Congress IX in Washington D.C. The results are from the company’s LYNX-1 phase 3 cli
- Iantrek Announces Positive Efficacy and Safety Profile of its Bio-Interventional Technologyhttps://modernod.com/news/iantrek-announces-positive-efficacy-and-safety-profile-of-its-bio-interventional-technology-to-enhance-uveoscleral-outflow-in-glaucoma-patients/2482707/Iantrek Corporation today announced positive results from its 2-year prospective clinical study evaluating its bio-reinforced cyclodialysis technology. The study, published in Ophthalmology Science, affirms the safety and efficacy of Iantrek’s bio-interventional technology to enhance&n
- Iluvien Earns FDA Approval for Expansion to Treat Chronic Posterior Uveitishttps://modernod.com/news/iluvien-earns-fda-approval-for-expansion-to-treat-chronic-posterior-uveitis/2482704/ANI Pharmaceuticals announced that they the FDA has approved an expanded label for Iluvien to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). “Iluvien's expanded label and the strengthening of our pa
- Atsena Granted FDA Fast Track Designation for Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-fast-track-designation-for-gene-therapy-to-treat-x-linked-retinoschisis/2482699/Atsena Therapeutics announced that the FDA has granted Fast Track designation for gene therapy product candidate, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). ATSN-201 leverages AAV.SPR, the company’s novel spreading capsid, to achieve therapeutic levels of g
- RadiusXR and Glaukos Announce a New Collaboration with Topcon for the Launch of Inspire Visual Field Solutionhttps://modernod.com/news/radiusxr-and-glaukos-announce-a-new-collaboration-with-topcon-for-the-launch-of-inspire-visual-field-solution/2482695/Topcon Healthcare, RadiusXR, and Glaukos announced a new collaboration and the launch of RadiusXR’s new wearable vision testing platform called Inspire. Together, the companies aim to expand access and enable doctors to provide visual field exams and educat
- Lumata Health Secures $23 Million Series B Fundinghttps://modernod.com/news/lumata-health-secures-23-million-series-b-funding/2482691/Lumata Health announced that it has raised $23 million in Series B funding, bringing its total raised since inception to $36 million. Lumata said the investment will enable the company to meet growing demand and further enhance the data-driven technology powering its patient adherence s
- Latinos En Optometry and VSP Vision Launch New Series Focused on Enhancing Cultural Competencyhttps://modernod.com/news/latinos-en-optometry-and-vsp-vision-launch-new-series-focused-on-enhancing-cultural-competency/2482689/Latinos en Optometry has collaborated with VSP Vision to launch a new blog series called “Cultural Responsiveness.” The initiative seeks to support both existing and prospective practitioners in understanding the importance of healthcare services that are responsive to the s
- Haag-Streit Launches METIS 900 Ophthalmic Surgical Microscopehttps://modernod.com/news/haag-streit-launches-metis-900-new-ophthalmic-surgical-microscope/2482687/Haag-Streit announced the launch of the METIS 900 ophthalmic microscope system. According to Haag-Streit, the METIS 900 was designed to maximize clarity and precision of visualization during surgeries, as well as the surgeon’s comfort. Programmable hand and/or foot switches
- Opthea Publishes Phase 2b Trial Data for Wet AMDhttps://modernod.com/news/opthea-publishes-promising-phase-2b-trial-data-for-wet-amd/2482685/Opthea announced new data from the phase 2b clinical trial using sozinibercept to treat wet age-related macular degeneration (AMD). The results were published in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. Opthea’s complete phase 3 wet AMD
- FDA Expands Label for Izervay for GA Allowing for No Limitation on Duration of Dosinghttps://modernod.com/news/fda-expands-label-for-izervay-for-ga-allowing-for-no-limitation-on-duration-of-dosing/2482665/The FDA has approved an expanded label for Astellas Pharma's geographic atrophy drug Izervay (avacincaptad pegol intravitreal solution), allowing the drug to be used without a limitation on duration of dosing. The approval, which provides physicians and pat